- Home
- MRT vs SGMT Comparison
MRT vs SGMT Comparison
Compare MRT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRT
- SGMT
- Stock Information
- Founded
- MRT 2018
- SGMT 2006
- Country
- MRT Turkey
- SGMT United States
- Employees
- MRT N/A
- SGMT N/A
- Industry
- MRT Rental/Leasing Companies
- SGMT
- Sector
- MRT Consumer Discretionary
- SGMT
- Exchange
- MRT Nasdaq
- SGMT Nasdaq
- Market Cap
- MRT 228.0M
- SGMT 230.3M
- IPO Year
- MRT N/A
- SGMT 2023
- Fundamental
- Price
- MRT $2.51
- SGMT $6.76
- Analyst Decision
- MRT Strong Buy
- SGMT Strong Buy
- Analyst Count
- MRT 2
- SGMT 7
- Target Price
- MRT $6.00
- SGMT $26.57
- AVG Volume (30 Days)
- MRT 39.5K
- SGMT 536.5K
- Earning Date
- MRT 01-01-0001
- SGMT 11-12-2025
- Dividend Yield
- MRT N/A
- SGMT N/A
- EPS Growth
- MRT N/A
- SGMT N/A
- EPS
- MRT N/A
- SGMT N/A
- Revenue
- MRT $18,659,655.00
- SGMT N/A
- Revenue This Year
- MRT $83.87
- SGMT N/A
- Revenue Next Year
- MRT $115.34
- SGMT N/A
- P/E Ratio
- MRT N/A
- SGMT N/A
- Revenue Growth
- MRT N/A
- SGMT N/A
- 52 Week Low
- MRT $1.77
- SGMT $1.73
- 52 Week High
- MRT $3.89
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- MRT 53.11
- SGMT 36.86
- Support Level
- MRT $2.38
- SGMT $6.77
- Resistance Level
- MRT $2.52
- SGMT $7.35
- Average True Range (ATR)
- MRT 0.08
- SGMT 0.42
- MACD
- MRT 0.01
- SGMT -0.01
- Stochastic Oscillator
- MRT 59.26
- SGMT 0.90
About MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.